Study of Peptidyl Arginine Deiminases 4 (PAD 4) Antibodies in Rheumatoid Arthritis Patients | ||||
| Egyptian Journal of Rheumatology and Clinical Immunology | ||||
| Article 9, Volume 4, Issue 1, January 2016, Page 49-58 PDF (209.03 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejrci.2015.4477 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Darwish El-Hallous1; Nevine Mohannad2; Maher Kamel3; El-Sayed Radwan4 | ||||
| 1Departments of Internal Medicine, Alexandria University | ||||
| 2Alexandria University Hospitals | ||||
| 3Medical Biochemistry , Alexandria University; Alexandria; Egypt | ||||
| 4Damanhour Teaching Hospital, Alexandria University; Alexandria; Egypt | ||||
| Abstract | ||||
| Rheumatoid arthritis (RA) is one of the most commonly occurring form of inflammatory polyarthritis. If untreated, 20%–30% of RA patients become debilitated within the first three years following initial diagnosis. The clinical examination often fail to identify patients with early RA partly due to heterogeneity of disease presentation and course. To meet the need for improved diagnostic and prognostic tests, various serum biomarkers are being assessed, including a wide range of autoantibodies. Autoantibodies against peptidyl arginine deiminase type 4 (PAD-4) have recently been described as a specific biomarker in subjects with clinically apparent RA. In this study, we tested the presence of anti-PAD4 antibodies in 40 Egyptian subjects with RA and their first degree relatives in order to determine whether these autoantibodies play a role in early disease evolution. In addition, we aimed to describe the Anti-PAD4 relation to anti-CCP autoantibodies, and potential associations with a more severe RA phenotype. The study was carried out on total of 100 subjects divided into; 40 RA patients, 40 of first degree relatives (sister or brother) of RA patients and 20 matched controls. Results: The results indicated that the serum level of Anti-PAD 4 is increased in Egyptian RA patients and their relatives and has a positive association with disease activity. Also its level together with Anti-CCP provides a good diagnostic tool of RA. Conclusion: The serum level of Anti-PAD4 may provide diagnostic information of RA and may be considered as an early marker of the disease among the first degree relatives of RA patients. [Egypt J Rheumatology & Clinical Immunology, 2016; 4(1): 59-66] | ||||
| Keywords | ||||
| missed | ||||
|
Statistics Article View: 328 PDF Download: 429 |
||||
